Send to

Choose Destination
Clin Gastroenterol Hepatol. 2014 Feb;12(2):283-8. doi: 10.1016/j.cgh.2013.09.060. Epub 2013 Oct 6.

Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies.

Author information

Women's Medicine Collaborative, The Miriam Hospital, Brown University Alpert School of Medicine, Providence, Rhode Island. Electronic address:
Helen DeVos Children's Hospital, Michigan State University, Grand Rapids, Michigan.
Department of Medicine, University of Minnesota, Minneapolis, Minnesota.


Fecal microbiota transplantation (FMT) is an effective treatment for Clostridium difficile infections that are refractory to antibiotic therapy. Because of the important roles of the microbiota in the function of the gastrointestinal tract and other aspects of human physiology, there is a growing interest in studying FMT for other clinical indications. The US Food and Drug Administration regulates clinical studies to evaluate the safety and efficacy of FMT. Studies of FMT for recurrent Clostridium difficile infection or other indications could require submission of an investigational new drug application. Most academic physicians and investigators do not have the regulatory experience necessary to undertake this process. We provide guidance to researchers on the preparation and submission of investigational new drug applications to study FMT.


AE; CBER; CDI; CRF; Center for Biologics Evaluation and Research; Clostridium difficile infection; FDA; FMT; Food and Drug Administration; HIV; IB; IBD; IC; IND; IRB; R-CDI; SAE; adverse event; case report form; fecal microbiota transplantation; human immunodeficiency virus; inflammatory bowel disease; informed consent; institutional review board; investigational new drug; investigator's brochure; recurrent CDI; serious adverse event

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center